Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development of Pancreatic Cancer Diagnostic Method by Using a Reagent for Analyzing Purine Metabolite (Hypoxanthine, Xanthine) in Urine

NCT06291779 is registered in ClinicalTrials.gov with Ho-Seong Han as lead sponsor.

NCT NCT06291779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06291779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development of Pancreatic Cancer Diagnostic Method by Using a Reagent for Analyzing Purine Metabolite (Hypoxanthine, Xanthine) in Urine
Lead sponsor
Ho-Seong Han
Phase
Observational
Overall status
Unknown status
Start date
November 30, 2022
Completion date
May 31, 2024
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diagnosis, pancreas cancer